Complement Therapeutics Announces Strategic Manufacturing Collaboration with Pharmaron
London, UK – March 29th 2023 – Complement Therapeutics Ltd (CTx) and Pharmaron are delighted to announce a strategic partnership for the Development and Clinical Manufacture of lead investigational product (CTx001) – a Gene Therapy for the treatment of Geographic Atrophy (late dry age-related macular degeneration), which causes significant vision loss and is estimated to affect 5 million people globally.
The project commenced in December 2022 with initiation at Pharmaron’s state-of-art gene therapy clinical development and GMP manufacturing facilities in Liverpool, UK. The Pharmaron CMC team has a wealth of technical know-how and experience in the development of ocular gene therapy medicines.
CTx001 is in pre-clinical development as an Adeno Associated Virus (AAV) based gene therapy for the treatment of Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001 harnesses the unique mechanism of action of a highly potent complement regulator to maximise efficacy in a broad range of patients with complement-driven GA. This partnership will allow the delivery of clinical-grade drug products for the supply for first-in-human clinical trials anticipated to commence in H2 2024.
Dr. Rafiq Hasan, CEO of Complement Therapeutics said, “Collaborating with Pharmaron is a critical component in our strategy to bring CTx001 through clinical proof of concept. Their track record in delivering gene therapies for ophthalmic diseases, technical expertise and state-of-the-art facilities make them an ideal partner in delivering a robust and scalable CMC platform. Our team looks forward to a productive and collaborative partnership, accelerating the development of CTx001 in a cost-effective manner, with the ultimate aim to improve the quality of life of patients with GA.”
Dr. Derek Elliison, VP Biologics Services Europe, Pharmaron Biologics & CGT, commented, “I am extremely pleased that Complement Therapeutics, has recognised Pharmaron’s advanced analytical and process development capabilities to develop their lead investigational product. This project is a great fit for our multi-disciplinary expertise team given the many years’ prior experience working on gene therapy ophthalmic indications out of our Liverpool site and we are excited at the opportunity to make a difference in fighting this debilitating cause of vision loss in such a large patient group.
About Complement Therapeutics Ltd:
Complement Therapeutics Ltd (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
The Company’s lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
Contacts
For further information please contact:
Pharmaron:
Ellen Cabral
Senior Marketing Director
Tel: +1 617 901 2216,
Email:ellen.cabral@pharmaron.com
Complement Therapeutics:
Dr Rafiq Hasan
CEO
Email: info@complementtx.com